Oxytocin

• Reproduce the adult autism-trial doserecommended

  Off-label research dose from the 6-week adult RCTs reviewed in PMC5080861 (24 IU per dose; the trials gave it twice daily). Not an approved regimen.

• Label (obstetric, clinician-administered): postpartum bleeding 10 to 40 units in 1,000 mL IV, or 10 units (1 mL) IM after delivery of the placenta. Labor induction is IV infusion by pump only. These are not self-dosing figures.
• Research (off-label, not a label): intranasal 24 IU twice daily for 6 weeks in adult autism trials; 18 or 24 IU twice daily for 8 weeks in adolescents; single doses mostly 24 IU. Registered trials range 3 to 40 IU (PMC5080861).
• Community practice, not from a label or trial: no community dosing source was fetched, so none is encoded.

Route: Label: IV infusion or IM, in obstetric care. Research: intranasal spray. Subcutaneous self-injection has no sourced figure.

Timing: No reliable figure found in the sources; ask your prescriber or supplier.

• Label product is a ready 10 USP units/mL solution. The water in the protocol is arithmetic for a lyophilized research vial (100 IU + 1 mL gives 100 IU/mL, so 24 IU = 24 units), not a sourced instruction.

No reliable figure found in the sources; ask your prescriber or supplier.

Research courses were 4 days to 8 weeks; no sourced rest period.

Why:

• The sources give no off-cycle. Data beyond about 6 months are lacking (PMC5080861).

• Never draw into the same syringe as another compound; use separate syringes and distinct injection sites.

Prescription injectable approved for obstetric use; boxed warning: indicated for medical, not elective, induction of labor. Intranasal use for other purposes is off-label. Do not use outside obstetric care in pregnancy: it is contraindicated in several obstetric situations (label).

Common side effects:

• Water intoxication: oxytocin has an antidiuretic effect, and severe water intoxication with convulsions and coma has occurred with prolonged infusion; maternal death has been reported (label).
• Intranasal trials reported no severe adverse events and short-term use was well tolerated, but safety data beyond about 6 months and in females are limited (PMC5080861).

Stop and call your prescriber if:

• Headache, confusion, nausea or vomiting with swelling (possible low sodium)
• Seizure or fainting
• Pregnancy, or any uterine cramping or bleeding

Labs and monitoring:

• Serum sodium if there is any sign of water intoxication (inferred from the label's water-intoxication warning).

What sources report this compound changes, or say to check. A record of the evidence, not targets or advice.

• Fluid balance (water intoxication)Check itDrug label

  Label reports maternal death from oxytocin-induced water intoxication due to antidiuretic effect, higher risk with continuous infusion and oral fluids; serum sodium is not named in the label

  Oxytocin Injection USP label
• Maternal blood pressure and rhythmReported changeDrug label

  Label lists maternal hypertensive episodes (after vasoconstrictor with caudal block), arrhythmia and premature ventricular contractions

  Oxytocin Injection USP label

• Oxytocin Injection USP 10 units/mL label (indications, dosing, contraindications, water intoxication)
• PMC5080861: intranasal oxytocin in autism, doses and evidence (2016 review)